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ESCAPE at a glance 
Objectives of the project
Available data on the substances injected by users are 
based on self-reports collected in drug treatment 
registries or ad-hoc surveys. While these data are 
informative, they are often available only after some 
delay and are not analytically confirmed. Moreover, 
little is known about people who inject drugs that are 
not reached by drug services. The ESCAPE (European 
Syringe Collection and Analysis Project Enterprise) 
project seeks to complement existing data on 
substances injected by users, by providing timely and 
local information derived from the analysis of the 
residual content of used syringes.
A novel approach
A group of European researchers has developed an 
innovative method to obtain information on injected 
substances by chemically analysing the residual 
content of used syringes. For this study, syringes were 
collected from the bins of street automatic injection kit 
dispensers and at harm-reduction services in 
a network of six sentinel European cities: Amsterdam, 
Budapest, Glasgow, Helsinki, Lausanne and Paris. The 
contents of 1 521 used syringes were analysed in five 
laboratories using chromatographic and spectroscopic 
methods.
Main results
■■ Injected substances vary between and within cities.
■■ Traces of stimulants (cocaine, amphetamines and 
synthetic cathinones) were found in a high 
proportion of the syringes tested in each of the 
cities. This may indicate a high prevalence of 
stimulant use among people who inject drugs.
■■ Injection of opioid substitution medications, most 
notably buprenorphine, as well as benzodiazepines 
and other medications is common in some cities.
■■ Half of the tested syringes contained residues of 
two or more drugs, which may indicate that people 
who inject drugs often inject more than one 
substance. The most frequent combination was 
a mix of a stimulant and an opioid; benzodiazepines 
were often found in syringes that also contained 
traces of opioids.
Main limitations
■■ A high number of syringes containing residues of 
stimulants could reflect the higher frequency of 
injecting among stimulant users, rather than a high 
prevalence of stimulant use among people who 
inject drugs.
■■ Drugs found in syringes may originate from blood 
drawn into the syringe during an injection. This 
would indicate that the user had consumed the drug 
prior to the injection, possibly through other modes 
of administration.
■■ It was not possible to distinguish a syringe 
containing residues of multiple drugs that has been 
used once, from a syringe that has been reused by 
one user or used by several for different drugs.
Key issues
■■ The ESCAPE approach provides local and timely 
information that can be used for city-level 
monitoring and interventions.
■■ This study documents the substances and 
combinations of substances that were injected in 
the participating cities.
■■ The injection of stimulants has implications for the 
risk of blood-borne and sexually transmitted 
infections such as HIV and hepatitis B and 
C viruses.
■■ The injection of multiple substances elevates the 
risk of adverse health consequences and overdose 
deaths.
What’s next?
Future campaigns will aim at collecting syringes from 
other settings and will allow the monitoring of trends 
over time. The network will be expanded to include 
more cities, in order to provide a more representative 
picture of the European situation and to advance 
knowledge on local injecting practices.
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l Study rationale and methods
While evidence from drug treatment centres suggests that 
the prevalence of injecting drug use is declining in the 
European Union (EMCDDA, 2015), the burden of disease 
associated with injecting remains high (Degenhardt et al., 
2017). The risk of overdose death and infectious diseases 
associated with this mode of administration is also high. 
The injection of stimulants — including cocaine and 
synthetic cathinones — has been linked to increased risk 
of HIV and HCV transmission, through increased frequency 
of use and sharing of injecting paraphernalia (Giese et al., 
2015). Knowledge of what substances are being injected 
in a city or country is necessary to guide prevention 
strategies and plan the provision of treatment, as well as to 
inform law enforcement agencies. Furthermore, identifying 
associated risk factors, such as reuse and sharing of 
injecting material, is useful to assess and improve harm-
reduction interventions
Available data on the substances injected by users are 
based largely on self-reports collected in drug treatment 
registries or ad-hoc surveys (DRUCK Study group et al., 
2016). Data from drug treatment centres collated at the 
national level show that the majority of people entering 
treatment who report injection as their main mode of 
administration identify an opioid (usually heroin) as their 
primary problem drug (see Table 1). While these data are 
useful, they are generally available only after some delay. 
Moreover, people who inject drugs may not wish to 
disclose the substances they inject or may not be aware of 
the composition of the substances they inject. Little is 
known about people who inject drugs that are not reached 
by drug services. To address such gaps in the data, a group 
of European researchers developed an innovative method 
to obtain information on injected substances by analysing 
the residual content of discarded syringes collected from 
the bins of street automatic injection kit dispensers (AIKD) 
or at harm-reduction services (Lefrançois et al., 2016; 
Néfau et al., 2015; Péterfi et al., 2017). The current study 
draws on this innovative methodology.
This publication provides an overview of the main findings 
of the European Syringe Collection and Analysis Project 
Enterprise (ESCAPE) 2017 campaign. ESCAPE was 
established in 2017 by the European Monitoring Centre for 
Drugs and Drug Addiction (EMCDDA) with a network of six 
sentinel European cities: Amsterdam, Budapest, Glasgow, 
Helsinki, Lausanne and Paris. It aims to identify which 
drugs are injected in the six cities by analysing the content 
of used syringes.
TABLE 1 
Number and percentage of drug treatment entrants reporting current injecting by self-reported primary drug and 
estimated population size of current injectors aged 15-64, in countries hosting ESCAPE sentinel cities
Finland France Hungary Netherlands
Scotland (United 
Kingdom)
Heroin 4 (1.2 %) 1 257 (58.8 %) 69 (35.9 %) 36 (66.7 %) 1 478 (95.4 %)
Buprenorphine 201 (60.7 %) 266 (12.4 %) 0 (0.0 %) 0 (0.0 %) 8 (0.5 %)
Methadone 0 (0.0 %) 10 (0.5 %) 11 (5.7 %) 0 (0.0 %) 1 (0.1 %)
Fentanyl and its derivatives 2 (0.6 %) 3 (0.1 %) 0 (0.0 %) 0 (0.0 %) 1 (0.1 %)
Other opioids 23 (6.9 %) 294 (13.7 %) 7 (3.6 %) 3 (5.6 %) 2 (0.1 %)
Cocaine 0 (0.0 %) 243 (11.4 %) 2 (1.0 %) 5 (9.3 %) 44 (2.8 %)
Amphetamines 91 (27.5 %) 17 (0.8 %) 31 (16.1 %) 3 (5.6 %) 5 (0.3 %)
Methamphetamines 1 (0.3 %) 1 (0.0 %) 0 (0.0 %) 1 (1.9 %) 0 (0.0 %)
Cathinones 4 (1.2 %) 17 (0.8 %) 0 (0.0 %) 0 (0.0 %) 0 (0.0 %)
MDMA 0 (0.0 %) 1 (0.0 %) 13 (6.8 %) 0 (0.0 %) 0 (0.0 %)
Other stimulants 3 (0.9 %) 10 (0.5 %) 25 (13.0 %) 1 (1.9 %) 0 (0.0 %)
Benzodiazepines 1 (0.3 %) 4 (0.2 %) 0 (0.0 %) 0 (0.0 %) 2 (0.1 %)
Others 1 (0.3 %) 16 (0.7 %) 34 (17.7 %) 5 (9.3 %) 9 (0.6 %)
Total 331 2 139 192 54 1 550
Estimated number of people 
who inject drugs and 
prevalence per 1 000 
population aged 15-64
15 611 (4.6 ‰) 108 607 (2.68 ‰) 6 707 (0.98 ‰) 840 (0.08 ‰) 23 933 (3 ‰)
Note: Treatment entry data for 2016, except for the Netherlands (2015) and Scotland (2016/17). Estimates of people who inject drugs are for 2015, except for 
Finland (2012) and the United Kingdom (2006). 
Source: EMCDDA.
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l Syringe collection, preparation and analysis
In each of the six cities, a local research team was 
responsible for the sampling, collection and preparation of 
the syringes. The contents of the syringes were analysed 
by the team that collected them, with the exception of 
syringes collected in Amsterdam, which were analysed by 
the Lausanne research team. Depending on the availability 
of potential sampling locations and the local context, 
between 1 and 5 collection sites were selected in each city 
in order to maximise geographical coverage. The total of 18 
sites across the 6 cities comprised 11 low-threshold 
facilities offering face-to-face needle and syringe exchange 
(NSP), 1 drug consumption room, and 6 street bins from 
automatic injection kit dispensers (AIKD) (see Figure 1). 
The social and demographic characteristics of the people 
who inject drugs served by each site broadly reflected the 
heterogeneity found between and within European cities 
(see Table 2).
Glasgow
Paris
Amsterdam
Lausanne
Budapest
Helsinki
 
 
Automatic injection kit dispensers with bins (AIKD)
 
 
 
 
Drug consumption rooms
   
People who inject drugs can anonymously discard used syringes into an appropriate container in the 
low-threshold facility and receive in turn new injection paraphernalia. 
Street-mounted automatic dispensers enable the self-operated exchange of injection equipment. Used 
syringes can be deposited in a special container in return for a token, which can be exchanged for an 
injection kit from the dispenser. AIKD has the potential to reach injecting drug users who are not in 
contact with health and social services. 
In drug consumption rooms, the exchange process is reversed. A sterile syringe is given to a user. After the 
supervised injection, the user disposes the syringe in a container located in the supervised injection room.  
Face-to-face needle and syringe exchange programmes (NSP)
 
FIGURE 1
Syringe collection sites, by city and type of service, ESCAPE, 2017
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Syringes were collected between August and November 
2017. The research teams aimed at collecting 300 syringes 
per city, equally distributed across sites, which was 
considered a representative sample. The number of 
syringes collected per site depended on the number of 
sites selected in each city; the minimum required sample 
per site was set at 30 syringes. Where possible, syringes 
were collected from different containers to minimise the 
risk of collecting too many syringes from the same NSP 
user. When collecting used syringes from AIKD, the 
syringes in bins were shuffled before sampling. Syringes 
with damaged barrels were excluded and larger volume 
syringes (>1 ml) were only collected and tested in Glasgow 
and Helsinki. In Helsinki and Paris, needleless syringes 
were excluded, while in Amsterdam syringes with 
a crooked needle were excluded. In Glasgow, syringes 
used for image and performance enhancing drugs were 
excluded. In Helsinki, Lausanne and Paris, syringes were 
TABLE 2
Socio-demographic characteristics of population living in the area of ESCAPE study sites, 2017
City Estimated number 
of people currently 
injecting drugs
Number of sterile 
syringes distributed
Syringe collection sites Number of 
syringes 
collected and 
analysed
Amsterdam
860 000 inhabitants 
(5 042/km2)
Between 150 and 
200
Three NSP services and one drug consumption 
room. The latter is located in the Red Light District 
and also provides sterile syringes. It is the only 
drop-in centre with a shelter for women. Clients of 
these services are aged between 22 and 71 years 
and are socially vulnerable. Self-reported 
substance use includes heroin, cocaine, 
methadone, amphetamine, cannabis and alcohol.
81
Budapest
2 000 000 
inhabitants  
(3 314/km2)
6 000 In 2017, an 
estimated 115 500 
syringes were 
distributed in 
Budapest (35 000 by 
the NSP described 
below).
One face-to-face NSP. This low-threshold service is 
located in a poor neighbourhood, where there is 
a concentration of homeless people and sex 
workers. The area is also popular among tourists.
226
Glasgow
621 020 inhabitants 
(3 555/km2)
5 500 350 436 needles 
and syringes were 
provided from all 
outlets in Glasgow 
city centre in 2017.
Two NSP services. One service is located at the 
edge of the city centre in a largely industrial area 
and includes a rehabilitation residential service. The 
other is located in the city centre in a mixed retail/
residential area, close to social services for the 
homeless.
195
Helsinki
643 272 inhabitants 
(3 002/km2)
8 500 In 2017, three of the 
five NSP described 
below provided 
a total of 1 732 462 
needles and 
syringes.
Five NSP. One site is located in the eastern part of 
downtown Helsinki, an area with social and health 
services for people who inject drugs, known for 
drug trade and drug users. A second site is located 
in the northern part of downtown Helsinki, in 
a housing unit with 100 residents with substance 
use and/or mental health problems. A third site is 
located close to the city centre, near a similar 
housing unit. The two remaining sites are located 
further east, one in a business and residential area 
with an open drug scene and trade, and the other in 
a residential area with a higher than average 
concentration of social housing.
284
Lausanne
144 597 inhabitants 
(3 395/km2)
No data 157 238 syringes 
were distributed in 
2017.
There is only one bin of AIKD in Lausanne. It is 
located in the central neighbourhood of Lausanne, 
served by two metro stations. During the day, 
people from diverse socio-economic background 
use this area. In the evening, it has significant 
nightlife activity and hosts marginalised groups.
233
Paris
2 140 526 
inhabitants 
(20 000/km2)
26 328 in the whole 
Paris region 
(Ile-de-France)
656 000 syringes 
were distributed in 
Paris in 2015.
Five bins of AIKD. Three sites are located next to 
train stations. In one of these sites users of AIKD 
include low-income and homeless people. The 
other two stations are busy public transport hubs 
frequented by people from diverse socio-economic 
backgrounds. The remaining two sites are located 
near metro stations in affluent neighbourhoods 
with well-integrated populations. One of the latter is 
famous for its nightlife.
259
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FIGURE 2
Extraction of syringe content for chemical analysis, ESCAPE, 2017
visually assessed to identify broken needles and erased 
graduation marks, which were taken as a proxy for attrition 
and as a possible indication of reuse.
To reduce the risks associated with handling used injection 
material, a number of safety precautions were taken, such 
as wearing personal protective equipment (including 
safety goggles, gowns and anti-scratch gloves), having 
access to a bleach basin, and using sharps containers to 
recover the syringes.
Syringes were transported from the collection sites to the 
laboratory within 48 hours of being deposited, in order to 
limit degradation of the content. Once in the laboratory, 
syringes were stored at 4 °C (for analysis within 48 hours) or 
at –20 °C (for analysis beyond 48 hours). Syringe contents 
were extracted in methanol: the syringe was filled and 
emptied five times, and the contents were collected in 
a clean test tube (Figure 2). The recovered methanol solution 
was then filtered before analysis in order to eliminate solid 
particles, which could damage the analytical instruments.
l Target substances
Up to 115 drugs were tested for, depending on the 
analytical method used (see Appendix 1). In addition, 
syringes were screened for the presence of some 
metabolites, degradation products and adulterants (see 
the box ‘Key terms’). Inactive diluents and binders were not 
considered in this study. The list of substances tested for is 
provided in Appendix 1, detailing which cities performed 
each test.
The analytical methods employed in this project have been 
previously used in similar studies: gas chromatography 
(GC), ultra-high or high performance liquid 
chromatography (UHPLC/ HPLC) coupled with mono or 
tandem mass spectrometry (MS or MS/MS) (Lefrançois et 
al., 2016; Maurer, 1992, 1999; Néfau et al., 2015; Péterfi et 
al., 2017). In Glasgow, Helsinki and Paris, chemists used 
a target-compounds method, allowing them to detect only 
the compounds marked in Appendix 1. Samples from 
Amsterdam, Budapest and Lausanne were analysed using 
a screening method that could potentially detect any 
compound, including all those listed in Appendix 1.
The results are presented by individual drug (cocaine, 
heroin, morphine, buprenorphine, methadone, ketamine) or 
by group of drugs (amphetamines, fentanyl and related 
substances, other opioids, synthetic cathinones, synthetic 
cannabinoids, benzodiazepines, phenidates, MDMA, other 
medications, other amphetamines and other drugs) (see 
Appendix 1). Only syringes that were positive for at least 
one substance (excluding metabolites and adulterants) 
were included in the analysis.
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Key terms
Adulterant: A pharmacologically active compound 
that dealers mix with drugs to increase the volume of 
the product in order to maximise profits. For instance, 
levamisole — originally an anthelmintic medication, 
which has some antidepressant properties — is 
a common adulterant of cocaine. Pharmacologically 
inert diluents (such as sugar) were not screened for 
in this study.
By-product of production: Some drugs may be the 
result of the production process of another drug. For 
instance, codeine traces might be found in heroin.
Degradation product: A compound resulting from the 
natural breakdown of a drug over time. The 
degradation of a drug can occur in the syringe. For 
instance, heroin will naturally degrade into 6-MAM 
and morphine. In the analysis, any syringe testing 
positive for 6-MAM in the presence of either 
morphine or codeine was assumed to have once 
contained heroin and was classed as a ‘heroin 
syringe’.
Drug: A psychoactive substance consumed with the 
aim of altering the user’s mood and perception, 
through its effect on the central nervous system.
Drug group: In order to simplify the presentation of 
results for the large number of substances covered in 
this study, drugs were grouped according to their 
public health relevance and on the basis of their 
shared characteristics. The groups may thus combine 
chemical, pharmacological and use perspectives. For 
example, heroin and methadone are reported 
separately from ‘other opioids’ and ‘other 
medications’, respectively.
Metabolite: Metabolites are residues of a drug after it 
is broken down in the body. They can be found in the 
blood, urine or faeces of users after consumption of 
the drug regardless of the route of administration. 
Blood containing metabolites can enter a syringe 
during injection. In this study, tests were carried out 
for metabolites of heroin (6-monoacetylmorphine, 
6-MAM), cocaine (benzoylecgonine) and 
benzodiazepines (7-aminoclonazepam). Some 
metabolites, for instance 6-MAM, can also result 
from degradation. Syringes testing positive only for 
metabolites were excluded from the analysis.
l Detected drugs
l Regional and local variations
The research teams collected a total of 1 676 syringes in 
the six cities. The results of the qualitative chemical 
analysis were obtained for 1 521 of the 1 676 syringes 
(91 % of collected syringes). Analysis was not performed 
on blocked syringes that could not be rinsed. At least one 
drug was found in 1 278 syringes (84 %); 243 syringes 
(16 %) did not test positive for any drug; of these, 210 did 
not test positive for any screened substance and 33 tested 
positive for only metabolites or adulterants. There are four 
possible explanations for none of the tested substances 
being detected in a syringe: the syringe was not used; it 
was used and then thoroughly washed; it was used and the 
substance(s) degraded to undetectable levels; it was used 
to inject other substances, such as pharmacologically 
inactive compounds or drugs not included in the screening 
protocol.
Overall, the drugs most often found in the syringes were 
cocaine, heroin, cathinones, buprenorphine and 
amphetamines, with considerable differences across cities 
(see Figure 3). Traces of 46 different drugs were identified 
in the syringes analysed in the study. Heroin was the most 
commonly detected drug in Amsterdam, and it was found 
in almost half of the syringes in Glasgow and over one-third 
of those in Lausanne — two cities where cocaine 
dominated. In Helsinki, more than half of the samples 
tested positive for buprenorphine or amphetamines. 
Synthetic cathinones were found in 8 out of 10 of samples 
from Budapest and in 4 out of 10 from Paris. 
Benzodiazepines were often found in syringes from 
Lausanne and Helsinki. Substances grouped as ‘other 
medications’ were detected in every fifth syringe in 
Helsinki.
Although the number of syringes collected does not 
directly reflect the number of individuals providing them, 
some of the regional specificities observed are in line with 
self-reported data from drug treatment centres and 
surveys. In Finland, among those entering drug treatment 
in 2016 who reported injecting, the most commonly 
reported primary drugs were buprenorphine (66 %) and 
amphetamines (30 %). In the Netherlands, where the 
number of people who inject drugs is relatively small, 80 % 
of injectors entering drug treatment in 2015 reported 
heroin as their primary drug. In Hungary, while heroin is the 
drug injected by the majority of treatment entrants who 
report this mode of administration, self-reported data from 
NSP services have shown the growing importance of 
synthetic cathinones among injectors (reported by 80 % of 
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NSP clients in 2015), which was also confirmed by 
a similar analysis of syringe residues (Péterfi et al., 2017). 
In Glasgow, unpublished 2018 data from NSP services 
showed that heroin and cocaine were injected by most 
clients, with 82 % injecting heroin, 77 % cocaine and 26 % 
a combination of heroin and cocaine in the last 6 months. 
In the current study, after accounting for heroin 
metabolites, 49 % of the syringes from Glasgow tested 
positive for heroin and 80 % for cocaine.
This pattern, however, is not reflected in the Scottish drug 
treatment data, where heroin is named as the primary 
problem drug by 95 % of treatment entrants, compared 
with only 3 % for cocaine (see Table 1). Similarly, syringe 
residues from Paris do not reflect the latest 2017 national 
treatment data from France (see Table 1), where heroin 
was reported by the majority of injectors. In the ESCAPE 
study, heroin came third, after cathinones and cocaine. The 
discrepancy may be partially explained by the different 
coverage of the data sources: syringe residues reflect the 
local situation, whereas the treatment data are national. 
Moreover, in Paris, syringes were collected only from street 
bins and not from drug services, where surveys are 
conducted. ESCAPE provides analytically confirmed 
results (in contrast to self-reports in treatment data and 
surveys). Importantly, it is likely to reach populations that 
are not in contact with any health services and gives 
a snapshot of currently injected substances, which may 
not be reflected in treatment demands until some time in 
the future.
Results from Paris, and to some extent Helsinki, also 
suggest in-city variation in drugs injected, which likely 
reflects the different socio-demographic profiles of people 
who use drugs across the sites. In Paris (Figure 4), cocaine 
and opioids were most commonly found in syringes 
collected near train stations in the north of the capital — 
areas frequented by marginalised and impoverished users. 
Synthetic cathinones, on the other hand, were the 
dominant group detected in syringes from the west and 
the east of the city — neighbourhoods frequented by more 
affluent and socially integrated users.
In a previous study conducted in 2014, cocaine was the 
only substance detected in syringes collected from the 
western site (C) (Néfau et al., 2015). In 2017, synthetic 
cathinones were found in 98 % of the syringes collected 
from the same site, indicating a new local trend and 
demonstrating the capacity of this method to quickly detect 
such changes and inform services that may address them.
FIGURE 3
Percentage of syringes by detected drug group, by city, ESCAPE 2017
Budapest
Paris
HelsinkiGlasgow
Amsterdam
Lausanne
Heroin
Cocaine
Methadone
Morphine
Other
opioids
MDMA
5 %
95 % 43 %
Buprenorphine
Amphetamines
Naloxone
Benzodiazepines
Cathinones
Cocaine
MDMA
Piperidines
Ketamine
Methadone
Other
amphetamines
Other
medicines
Other
opioids
57 % 53 %
19 %
11 %
11 %
Cocaine
Heroin
MDMA
AmphetaminesMorphine
Other
opioids
Benzodiazepines
80 % 49 %
10 %
11 %
Cathinones
Amphetamines
Other
amphetamines
Heroin
BuprenorphineSynthetic 
cannabinoids
80 %15 %
10 %
6 %
Cocaine
Heroin
Benzodiazepines
Morphine
Methadone
Other
opioids
Piperidines
MDMA
72 % 36 %
23 %
6 %
Cathinones Cocaine
Heroin
Morphine
Buprenorphine
Piperidines
Amphetamines
Other
medicines
44 % 25 %
17 %
14 %
8 %
NB: Circle area is proportional to percentage of syringes in each location in which the substance was detected. More than one substance may be detected in 
a single syringe, therefore city totals may exceed 100 %.  
Number of syringes analysed: Amsterdam, 81; Budapest, 233; Glasgow, 195; Helsinki, 284; Lausanne, 233; Paris, 259.
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In Helsinki (Figure 5), the most striking difference is 
between sites located in the downtown area and those in 
the eastern part of the city. In the more socio-economically 
diverse downtown neighbourhoods, amphetamines were 
detected in most syringes. In the eastern areas, where 
poorer segments of the population are concentrated, 
buprenorphine was detected in the majority of syringes, 
while more diverse, western parts of the city registered 
more syringes with amphetamines.
l Stimulant injection found in all cities
While opioids, which have traditionally been associated 
with injecting, were commonly found in syringes, the high 
proportion of syringes testing positive for stimulants, such 
as cocaine (Amsterdam, Glasgow, Lausanne), synthetic 
cathinones (Budapest, Paris) and amphetamines (Helsinki, 
Budapest), suggests that injecting stimulants is 
a widespread practice among people who inject drugs in 
these European cities. The high prevalence of stimulants in 
syringes could be associated with the higher injecting 
frequency typical of stimulant use (Platt et al., 2015). It 
could also be the result of traces of blood containing 
stimulants drawn into the syringe during injection but 
consumed prior to injection, possibly through other modes 
of administration. However, other data also point to high 
levels of stimulant injection among people who inject 
drugs. A high prevalence of synthetic cathinones injection 
among clients of low-threshold programmes in Hungary 
was reported in 2014 (>50 %) (Kapitány-Fövény and Rácz, 
2018). Similarly, among treatment entrants in Finland 
reporting injecting as a main route of administration, 
injection of amphetamine reached 28 % in 2016. In 
Glasgow, the 2015 HIV outbreak among people who inject 
drugs has been strongly linked, among other factors, to 
injecting cocaine (McAuley et al., forthcoming).
In a trendspotter study conducted in 2018 by the 
EMCDDA, an increase in cocaine powder injecting, alone 
or in combination with heroin, was reported in drug 
consumption rooms in France, Germany, Luxembourg, 
Spain and Switzerland. The study also highlighted an 
increasing trend in injecting cocaine base (crack), either 
FIGURE 4
Percentage of syringes by detected drug group, by site, Paris, ESCAPE 2017
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98 % 13 %
Cocaine
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alone or as a cheaper alternative to traditional heroin-
cocaine preparations. The data analysed here do not 
distinguish whether cocaine residues found in syringes 
were from cocaine hydrochloride or cocaine base. Field 
reports from Paris indicate that marginalised and 
homeless users inject crack cocaine, (EMCDDA, 2018b). In 
Scotland, the NESI study among NSP clients (Health 
Protection Scotland, 2017) suggests that powder cocaine 
is the form that is being injected.
Synthetic cathinones were found in a majority of syringes 
from Budapest. This class of substances first appeared on 
the local drug market after the heroin shortage in 2011, 
and cathinones have since presented a substantial 
challenge for harm reduction services. The shift towards 
cathinones was linked to increased frequency of injecting, 
reuse and sharing of syringes, and higher HCV prevalence 
among stimulant users. The main cathinones injected were 
pentedrone and MDPV (Tarján et al., 2015). Analysis of 
syringe residues has shown substantial temporal changes 
in the occurrence of different cathinones (Péterfi et al., 
2017). The current study did not identify any syringes with 
either pentedrone or MDPV. The most commonly found 
cathinones were N-ethylhexedrone (76 %) and 4-Cl-alpha-
PVP (45 %). In Paris, by contrast, 3-MMC or 4-MMC 
(mephedrone) (34 %) and 4-MEC (24 %) were the only 
cathinones detected. The analytical method used by the 
French team does not distinguish 3-MMC from 
mephedrone. It is likely, however, that 3-MMC is more 
commonly injected, as 4-MMC (mephedrone) has been 
listed as a controlled substance since 2010 and 3-MMC 
was the most frequently seized new psychoactive 
substance in 2017 (Néfau, 2018). In Helsinki, six different 
cathinones were detected in syringes, but less frequently; 
the most common cathinone was alpha-PVP (4 %).
MDMA was detected in Amsterdam (1 syringe), 
Lausanne (3), Helsinki (8) and Glasgow (22). In Glasgow, 
syringes containing traces of MDMA represent 11 % of the 
sample, and most of these also tested positive for 
amphetamines. These figures contrast with treatment 
data, in which MDMA injecting is rarely reported at the 
national level with the exception of Hungary, where 13 out 
of 126 treatment entrants reporting injecting as a route of 
FIGURE 5
Percentage of syringes by detected drug group, by site, Helsinki, ESCAPE, 2017
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administration mentioned MDMA as their primary drug. 
MDMA may have been introduced into syringes through 
the blood of users, or as an adulterant. Selection bias also 
cannot be ruled out in the case of Glasgow, where tested 
syringes might have come from a small number of users.
l Injecting opioid substitution medications
Evidence shows that opioid substitution treatment 
improves mental health and reduces illicit opioid use, risk 
behaviour and mortality (EMCDDA, 2017; WHO, 2009). The 
main opioid substitution medications prescribed in Europe 
are methadone (63 % of substitution treatment clients) 
and buprenorphine (35 %); slow-release oral morphine and 
diacetylmorphine (medical grade heroin) are used to 
a much lesser extent (3 %) (EMCDDA, 2018a). Diversion 
and misuse of opioid substitution medications have been 
reported (EMCDDA and Europol, 2016), but there is 
currently no systematic monitoring in place, and empirical 
data on the extent of their misuse are lacking. The 
presence of these substances in syringes may be an 
indication of such misuse.
This study detected buprenorphine in most of the syringes 
tested in Helsinki (57 %), where it was the most frequently 
detected substance. Buprenorphine was also found in 
syringes from Paris (9 %) and Budapest (2 %). These 
findings are broadly in line with national data on drug 
treatment: 80 % of opioid users entering treatment in 
Finland in 2016 reported use of buprenorphine, while it 
was reported by 10 % of treatment entrants in France and 
by none in Hungary and the Netherlands.
In Helsinki, about one-fifth of the syringes testing positive 
for buprenorphine also contained traces of naloxone. This 
finding points to the misuse or diversion of Suboxone — 
a formulation that combines buprenorphine with the opioid 
antagonist naloxone, in order to discourage injection. In 
Finland, Suboxone is prescribed to 62 % of opioid 
substitution clients; only 2 % of opioid substitution clients 
are prescribed buprenorphine alone. The disproportionately 
low occurrence of the buprenorphine-naloxone 
combination in syringes, however, suggests that most of 
the buprenorphine that is injected in Helsinki is not 
diverted from locally prescribed medication. Rather, 
evidence from seizures suggests that it is increasingly 
smuggled from France via Sweden (EMCDDA and Europol, 
2016). The presence of naloxone in some syringes 
supports previous concerns that Suboxone may be 
misused and injected, and that naloxone does not entirely 
attenuate the effect of buprenorphine (Alho et al., 2007; 
Strain et al., 2000). In France, 61 % of opioid substitution 
clients are prescribed buprenorphine. Among those, 7 % 
are prescribed Suboxone. Naloxone was not detected in 
buprenorphine syringes from Paris.
Methadone was only detected in 13 syringes: 4 in both 
Amsterdam and Helsinki, and 5 in Lausanne. However, it is 
prescribed to more than three-quarters of opioid 
substitution clients in Hungary, the Netherlands, Scotland 
and Switzerland. Injection of methadone syrup is difficult 
but has been documented; it requires dilution in water and 
often also the use of larger volume syringes (sometimes 
larger than 20 ml), which were not sampled in this study. 
This, together with the fact that more than half of the 
methadone clients in France receive the medication in the 
form of capsules designed to prevent injection (Roux et al., 
2011), could explain why methadone was not detected in 
any syringes collected in Paris, although the substance was 
mentioned in 31 to 45 % of drug-related deaths reported in 
France each year from 2010 to 2015 (Observatoire 
Français des Drogues et des Toxicomanies, 2018).
Morphine is sporadically prescribed as an opioid 
substitution medication in Switzerland (Besson et al., 
2014). It was detected in almost half of the syringes in 
Glasgow and Amsterdam, one-third of the syringes in 
Paris, and one-quarter of the syringes in Lausanne 
(Appendix 2). The presence of morphine in syringes is likely 
the result of heroin degradation, rather than intentional 
injection of the drug. Indeed, morphine was typically found 
in syringes that also contained traces of heroin or its 
metabolite 6-MAM. If the co-occurrence of morphine and 
6-MAM is considered as indicating heroin alone (as 
presented in Figures 3-5), the share of syringes with clear 
signs of having originally contained morphine decreases to 
1-6 % of syringes in Amsterdam, Glasgow and Lausanne. 
Paris, where 40 % of morphine-positive syringes did not 
test positive for any other compound (including heroin 
metabolites), seems to be the exception to the rule. This 
finding is consistent with data from the drug consumption 
room in Paris and other field reports, which show diversion 
and injection of morphine sulphate (an opioid analgesic) 
(Cadet-Taïrou and Gandilhon, 2014). The same field reports 
also suggest that larger syringes (2 ml) are the preferred 
choice for morphine sulphate injections. Therefore by 
collecting only 1 ml syringes, the sampling strategy may 
have led to this practice being undercounted in 
Amsterdam, Budapest, Lausanne and Paris.
l  Benzodiazepines injected with opioids or stimulants
Misuse of benzodiazepines among high-risk drug users is 
a recognised and widespread phenomenon. Evidence 
suggests that co-consumption of benzodiazepines 
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increases the risk of overdose among high-risk opioid 
users. Furthermore, injecting crushed and dissolved 
medications that are intended for oral administration puts 
users at higher risk of vascular complications and 
infections (Roux et al., 2011).
Benzodiazepines tested for in this study differed by city 
(see Appendix 1). Common benzodiazepines such as 
alprazolam, clonazepam, diazepam and midazolam were 
tested in all cities. Some new benzodiazepines, which may 
appear on the drug market from various illegal sources, 
were tested for in Amsterdam, Budapest, Glasgow, 
Helsinki and Lausanne.
The practice of injecting benzodiazepines seems to be 
limited to Helsinki (where 11 % of all syringes were positive 
for this group) and Lausanne (23 %). In Glasgow, one 
syringe was found to contain traces of diazepam, while 
benzodiazepines were not detected in any syringes from 
Amsterdam, Budapest or Paris. In Lausanne, midazolam 
accounted for almost all benzodiazepine-positive syringes, 
but it accounted for half of the benzodiazepine detections 
in Helsinki, where alprazolam, clonazepam, diazepam, 
oxazepam and temazepam were also detected. Injection of 
midazolam has been noted, in unpublished reports, by 
local social services in Lausanne, where alcohol tabs are 
provided to reduce risks associated with the injection of 
crushed and dissolved coated tablets.
Benzodiazepines may be used to self-medicate adverse 
effects of illicit drugs or medicate unrelated conditions. 
They may also be used recreationally, for their own effect 
or to moderate the effect of another drug (Jones et al., 
2012). In this study, most syringes testing positive for 
benzodiazepines also contained traces of at least one 
other substance. The literature links misuse of 
benzodiazepines predominantly to opioid users. This was 
the case in Lausanne, where benzodiazepines were most 
often found in syringes also testing positive for heroin. In 
Helsinki, just under one-third of the syringes containing 
traces of benzodiazepines also tested positive for 
buprenorphine. Reports have suggested that some opioid 
substitution clients use benzodiazepines to increase or 
prolong the effect of the substitution medication when 
under-dosed (Lofwall and Walsh, 2014). Irrespective of the 
possible motivations for combining benzodiazepines and 
buprenorphine, this practice increases the risk of 
respiratory depression and overdose, counteracting the 
ceiling effect of buprenorphine (Reynaud et al., 2002).
The analysis of syringe residues from Helsinki shows that 
benzodiazepines can also be associated with stimulant 
drugs. In the Finnish capital, half of the syringes containing 
traces of benzodiazepines tested positive for 
methamphetamine. Stimulant injectors may use 
benzodiazepines to ‘come down’, or to treat withdrawal and 
anxiety.
Two important aspects should be considered when 
interpreting these results. First, injecting may not be the 
preferred route of administration of benzodiazepines. The 
majority of those entering treatment for problems related 
to use of benzodiazepines in Europe report oral 
consumption; less than 1 % report injecting them. Second, 
it is possible that regardless of the original mode of 
administration, benzodiazepines found in a syringe may 
originate from blood introduced into the syringe during 
injection, potentially leading to an overestimation of their 
injection.
While people who inject benzodiazepines are only a small 
fraction of all benzodiazepine users, the overall burden of 
their misuse is high. This is supported by data from 
Scotland where, while only one syringe tested positive for 
benzodiazepines in Glasgow, more than half of the 
overdose deaths recorded in 2017 in Scotland were linked 
to benzodiazepines (National Records of Scotland, 2018).
Other medications than benzodiazepines were overall less 
often detected, although in Helsinki they were identified in 
almost every fifth syringe (19 %). Pregabalin (9 %) and 
gabapentin (5 %) were the ones most often detected. Both 
medications are reported to have sedative, euphoric and 
psychedelic effects, and a potential to develop 
dependence (Schifano et al., 2011).
l Absence of high-risk fentanyl
Fentanyl and related substances are highly potent 
synthetic opioids that have been linked to several fatal 
drug poisonings and are increasingly present on the 
European illicit drug market (EMCDDA, 2018a). These 
substances can be sold as heroin or mixed with heroin or 
cocaine, putting users at risk of overdose.
Deaths associated with fentanyl and fentanyl derivatives 
(i.e. substances that share a chemical scaffold with 
pharmaceutical fentanyl) have been reported in the United 
Kingdom, Finland, France and Hungary. Seizure data 
showing the presence of fentanyl derivatives on the drug 
market are available from Finland, France, the United 
Kingdom and, to a lesser extent, Hungary and the 
Netherlands. Nonetheless, neither fentanyl nor any 
fentanyl derivatives tested for in this study were found in 
the syringes. For instance, between 2012 and 2017, the 
French addictovigilance network reported 8 acute 
intoxications with fentanyl and 8 acute intoxications with 
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fentanyl derivatives (5 with ocfentanyl, including two 
deaths; 2 with carfentanil, and 1 with butyrylfentanyl) 
(Centre d’Evaluation et d’Information sur la 
Pharmacodépendance, 2017), yet there were no 
detections of these substances or other fentanyl 
derivatives in the syringes analysed in Paris. The absence 
of fentanyl and fentanyl derivatives in syringes may 
indicate that these substances are not commonly injected 
in the participating cities or that services where syringes 
were collected may not be frequented by their users. The 
results might also underestimate the injection of these 
substances, due to the degradation of the low 
concentrations usually involved, making them harder to 
detect. Additionally, four of the top five seized fentanyl 
derivatives in Europe (valerylfentanyl, 4-fluoro-isobutyryl-
fenatnyl, acryloyfentanyl and cyclopentylfentanyl) 
(EMCDDA, 2018a) were not included in the screening 
protocol for Paris.
In Helsinki, a low-dose synthetic opioid U-47,770 was 
detected in one syringe. The drug was linked to several 
deaths in Finland in the past two years (Kriikku, 2017).
l Polydrug use
Polydrug use refers to the consumption of more than one 
drug by an individual over a certain period of time. It is 
associated with increased psychopathology, more risk 
behaviours, lower treatment adherence and worse health 
outcomes (Connor et al., 2014). Polydrug use is common 
among high-risk drug users. It includes simultaneous use 
(or co-use) of different drugs, such as the simultaneous 
injection of heroin and cocaine known as ‘speedballing’ (or 
‘snowballing’ in Scotland). This pattern of use is difficult to 
assess with standard monitoring tools. The presence of 
multiple drugs in a syringe can be an indication of co-use 
and may help to identify commonly used combinations.
Overall, 54 % of the syringes tested contained traces of 
two or more drugs: 32 % of the syringes contained traces 
of two drugs, 18 % three, and 4 % four to seven drugs. 
Morphine and codeine were often detected in syringes 
testing positive for heroin, likely as by-products of 
synthesis, metabolites, or the results of heroin 
degradation. If 6-MAM in the presence of morphine or 
codeine is considered as an indicator of heroin, rather than 
a mixture of drugs (Appendix 2), the overall proportion of 
syringes with clear evidence of having contained multiple 
drugs drops to 50 %. On this basis, the percentage of 
syringes testing positive for two or more substances 
ranged from 34 % in Lausanne to 62 % in Helsinki and 
64 % in Budapest.
The most common combination found was heroin and 
cocaine, detected in 148 syringes (12 %). Additional drugs 
(other than morphine or codeine) were found in 15 % of the 
heroin-cocaine syringes (Figure 6). Heroin and cocaine 
was the most common combination in three cities: 
Amsterdam (42 % of syringes), Glasgow (36 %) and 
Lausanne (17 %). In Lausanne, more than one-third of the 
heroin-cocaine syringes also tested positive for 
benzodiazepines. The heroin-cocaine combination was 
rarely detected in syringes from Paris (2 %) and was not 
found at all in Budapest and Helsinki — two cities where 
heroin was detected in very few syringes. Those entering 
drug treatment who report heroin as a primary drug 
(regardless of the mode of administration) frequently 
report use of both heroin and cocaine. Co-injection of the 
two drugs is, however, less common than concurrent use.
In Helsinki, where the main injected opioid is 
buprenorphine and the main injected stimulants are 
amphetamines, 17 % of the syringes contained traces of 
both (and 76 % of these tested positive for at least one 
other drug). Other combinations of a stimulant and an 
opioid found in syringes included buprenorphine and 
cocaine in Paris, heroin and cathinones in Budapest and 
Paris, buprenorphine and cathinones in Budapest and 
Helsinki, and cocaine and methadone in Lausanne. These 
combinations may be an alternative to the heroin-cocaine 
mixture, when one or both is unavailable.
As mentioned above, benzodiazepines were often found in 
syringes in combination with other substances. In 
Lausanne and Helsinki, most of the syringes testing 
positive for benzodiazepines also contained traces of an 
opioid or a stimulant.
The majority (80 %) of syringes testing positive for 
a synthetic cathinone contained traces of at least one 
other drug. In more than two-thirds of these (69 %), 
another cathinone was detected. Cathinones were also 
found in combination with other substances, albeit less 
frequently. In Helsinki, they were detected with 
amphetamines and opioids. In Paris, cathinones were 
found in the presence of cocaine, while other new 
psychoactive substances (such as new amphetamines or 
synthetic cannabinoids) were found in the company of 
cathinones in syringes from Budapest.
Combinations of two or more stimulants (cocaine, 
amphetamine, methamphetamine or synthetic cathinone) 
were not uncommon and overall appeared in 10 % of 
syringes (4 % in Budapest, 5 % in Paris, and 6 % in 
Glasgow). In Helsinki, 32 % of syringes contained the 
residues of a mixture of stimulants, mostly of 
amphetamine and methamphetamine.
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It is important to note that the detection of multiple 
substances in a syringe does not necessarily imply 
intentional injected polydrug use. First, drugs may enter 
a syringe in blood drawn by the user during injection, and 
the methods used in this study are sufficiently sensitive to 
detect traces of drugs introduced in this manner. If, for 
example, a person has smoked cocaine prior to injecting 
heroin, and drawn blood into the syringe, it may test 
positive for the two drugs. Second, the detection of 
multiple substances in a syringe can be the result of 
adulteration not known to the user. Cheap stimulants such 
as amphetamines or cathinones are used by dealers to 
adulterate more expensive drugs (Giné et al., 2014). Third, 
some drugs are degradation products of other drugs. 
Examples of this are morphine from heroin and 
amphetamine from methamphetamine. Fourth, the 
detection of several substances in one syringe may be the 
consequence of reuse of the syringe by one or more users.
l Reuse and sharing of syringes
Users are exposed to increased health risks when they 
reuse injection equipment (damaged and non-sterile 
equipment causes wounds and skin infections) or share it 
with multiple users (transmission of blood-borne 
infections). Within the scope of this study, it was not 
possible to distinguish a syringe testing positive for 
multiple substances that has been used once 
(simultaneous or co-use), from a syringe that has been 
reused by one user (polydrug use), from a syringe that has 
been used by several users (sharing of syringes).
Research teams from Helsinki, Lausanne and Paris looked 
for erased graduation marks on syringes as a sign of 
attrition and as a proxy measure of reuse. In Lausanne, 8 % 
of collected syringes showed visible signs of attrition. The 
corresponding share for Helsinki and Paris was 3 %. This 
figure is lower than that presented in a 2015 survey among 
injectors in low-threshold services in France, where 15 % 
reported having injected with syringes that had been used 
by others or having passed their used syringes to others in 
the previous month (Cadet-Taïrou et al., 2018). Looking at 
visible signs of attrition as an indication of reuse has 
significant limitations. Erased graduations could be due to 
intended marking by the user to distinguish used syringes 
(therefore not necessarily implying reuse, quite the 
contrary). On the other hand, sharing of syringes among 
injectors can happen without causing any visible damage 
to the syringe. In both cases, the proxy of reuse might not 
reflect the true level of sharing among injectors, and 
surveys where users are asked about their sharing 
practices remain better measurement tools.
Comparing national-level data from NSPs and national 
estimates of the number of people injecting drugs provides 
a measure of the coverage of sterile syringe provision. In 
Finland, an estimated 370 sterile syringes were provided 
per person injecting drugs in 2017 (EMCDDA, 2018a); in 
France, the coverage was estimated at 113 sterile syringes 
per person injecting drugs per year in 2017. The WHO 
FIGURE 6
Most frequent combinations of drugs found in syringes ESCAPE, 2017
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target for the elimination of hepatitis B and C is 300 sterile 
syringes per user per year by 2030 (WHO, 2017).
l Adulteration
Adulterants are pharmacologically active substances, which 
may be toxic, have adverse consequences, and — similarly 
to polydrug use — may increase health risks for users. For 
instance, levamisole, a common adulterant of cocaine, has 
been linked to convulsions, insomnia, damage of white 
matter in the brain, weakened immune system and acute 
coronary syndrome (Brunt et al., 2017). Phenacetin, another 
cocaine adulterant, has neurotoxic and carcinogenic 
adverse effects (Solimini et al., 2017). Eight common 
adulterants were tested for in this study: dextromethorphan 
and levamisole in all cities; griseofulvine, paracetamol, 
caffeine, lidocaine and phenacetin in Amsterdam, Budapest 
and Lausanne; hydroxyzine in Amsterdam, Budapest, 
Helsinki and Lausanne. Inert diluents and binders were not 
included in the screening protocol. The analysis of 
adulterants was limited to syringes that tested positive for 
only one main drug.
Among the 237 syringes in which cocaine was the only 
drug detected, levamisole was present in 38 %, phenacetin 
in 29 %, caffeine in 19 % and lidocaine in 10 %. 
Hydroxyzine was detected in one syringe (0.4 %) and 
paracetamol in two (0.8 %) with cocaine. Cocaine is often 
described as the most adulterated drug (Kudlacek et al., 
2017), yet no adulterant was detected in half (53 %) of the 
syringes testing positive for cocaine. This finding might be 
related to recent changes in cocaine purity suggested by 
other sources (EMCDDA, 2018b).
Among the 134 syringes in which heroin was the only drug 
detected (besides morphine and/or codeine), caffeine was 
found in 50 %, paracetamol in 30 % and griseofulvine in 
9 %. Six heroin syringes (5 %) tested positive for 
phenacetin. Almost half of the heroin syringes (49 %) did 
not test positive for any of the screened adulterants; 19 % 
tested positive for one adulterant and 32 % for two or more.
Caffeine was the only adulterant detected in the presence 
of amphetamines. It was found in 14 out of 22 syringes 
(4 %) that tested positive for no drug other than 
amphetamine. It should be considered, however, that the 
presence of cathinones alongside amphetamine in 
syringes in Helsinki (8 % of all amphetamine syringes) may 
have been the result of adulteration rather than intentional 
polydrug use (Giné et al., 2014). Hydroxyzine was found in 
one of the 17 (6 %) syringes testing positive for 
methamphetamine and no other drug. While no 
adulterants were found in buprenorphine syringes, 
adulterants were detected in some syringes testing 
positive for methadone (caffeine, phenacetin and 
paracetamol). Phenacetin was also detected in one syringe 
testing positive for MDMA.
l Limitations
The first phase of this project was designed as a pilot study 
for the application of this innovative method, involving 
researchers in six sentinel European cities. The following 
caveats apply to the results presented here.
The number of syringes collected and tested cannot be 
translated into a number of individual users. A small 
number of users could contribute a disproportionately large 
number of syringes; for example, if some users brought 
back their syringes in bulk. In addition, some syringes may 
have been used by several people. The method therefore 
does not measure prevalence of injecting nor does it 
necessarily provide the relative prevalence of the different 
substances used among injectors. For example, a high 
number of syringes testing positive for stimulants could 
reflect the higher frequency of injecting among stimulant 
users, rather than a high prevalence of stimulant use 
among people who inject drugs.
While all laboratories screened for the most common 
drugs, the final list of screened substances varied between 
sites, depending on the laboratory methods used. In one 
city (Helsinki), syringes testing negative for a first list of 
substances were tested a second time for another set of 
substances. Some drugs (e.g. methadone syrup) are 
known to be injected in syringes larger than 1 ml. Only 
Glasgow and Helsinki collected syringes larger than 1 ml. 
The study might therefore have underestimated the 
presence of these drugs in cities where only 1 ml syringes 
were collected.
Drugs in syringes may degrade over time and might 
become undetectable. In the case of heroin, metabolites 
and degradation products indicate the presence of the 
drug in the syringes even after the heroin has degraded. 
This does not apply for other substances. The time lag 
between injection and collection was unknown for syringes 
from street bins and low-threshold services. In drug 
consumption rooms, however, syringes were collected 
immediately after injection.
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The detection of a drug in a syringe indicates that the 
syringe was used to inject the drug. There is, however, an 
alternative explanation. The drug may come from traces of 
blood originally drawn into the syringe during an injection. 
In such a case, the user would have consumed the drug 
prior to the injection, possibly through other modes of 
administration (e.g. smoking, snorting). If a metabolite is 
found, it is likely to have been detected from blood traces. 
Some metabolites, however, are not distinguishable from 
degradation products (e.g. 6-MAM). This study did not test 
for the presence of blood in syringes. It is therefore difficult 
to identify the source of the metabolite. For the analysis, 
any syringe testing positive for 6-MAM along with either 
morphine or codeine was assumed to have once contained 
heroin and was classed as a heroin syringe. Syringes in 
which only metabolites were detected were excluded from 
the analysis.
When a drug is found in a syringe, it is an indication that it 
has been injected intentionally by the user. However, 
dealers can mix the drug with pharmacologically active 
substances to increase the volume of the product 
(adulteration). In this case, the user might be injecting 
substances unintentionally. This study did not collect 
information directly from users. Thus it is not possible to 
distinguish intentional from unintentional use.
Within the scope of this study, it was not possible to 
distinguish a syringe with multiple drugs that has been 
used once (simultaneous or co-use), from a syringe that 
has been reused by one user (polydrug use), from a syringe 
that has been used by several users (sharing of syringes).
l Key issues
Within a global market for drugs, strong regional and local 
variations persist. It is important that public health 
responses to injecting drug use be tailored to local needs, 
defined by local data. The regional differences in the drugs 
injected reflect different geographical markets, with their 
own trafficking networks (EMCDDA and Europol, 2016) 
and users’ preferences. The results of this first European 
syringe collection campaign outlined some key patterns 
that have public health implications.
While heroin has traditionally been associated with 
injecting, in all six cities a high proportion of the syringes 
was found to contain traces of stimulants, which may 
indicate a high prevalence of stimulant use among people 
who inject drugs. The potentially high level of stimulant 
injection suggested by the results of the current study has 
public health implications. First, long-term stimulant use 
may cause serious cardiovascular diseases and result in 
psychiatric comorbidities. Second, the injection of cocaine, 
amphetamine or synthetic cathinones is associated with 
more frequent injections and unsafe sex (Cavazos-Rehg et 
al., 2009). HIV outbreaks among people who inject drugs in 
cities that have well-functioning harm reduction services 
(Giese et al., 2015; McAuley et al., forthcoming) are 
a strong signal that stimulant injection constitutes 
a particular challenge for public health. It requires scaling 
up harm reduction services in order to reduce the risk of 
blood-borne and sexually transmitted diseases.
Opioid substitution medications, most notably 
buprenorphine, can be misused and injected. The current 
study documents this practice in Helsinki and, to a lesser 
extent, in Paris. When taken according to medical 
prescription and combined with psycho-social support 
(WHO, 2009), opioid substitution treatment reduces illicit 
opioid use, risk behaviours and mortality and improves the 
mental health of patients. The misuse of opioid 
substitution tablets through injection, however, has been 
associated with fatal and non-fatal overdoses, and 
vascular and cutaneous complications (Bouquié et al., 
2014). Strategies to reduce diversion and injection of 
opioid substitution medications include prescription of 
formulations that are harder to inject (methadone, which is 
commonly prescribed in syrup or capsule formulation, and 
Suboxone, which contains naloxone). However, naloxone 
was detected in syringe residues, indicating injection of 
Suboxone. Other strategies to reduce misuse of opioid 
substitution medications include supervised dosing and 
the monitoring of prescriptions by health authorities 
(EMCDDA, 2017).
Half of the syringes tested contained traces of two or more 
drugs. Despite some limitations (it is not possible to 
differentiate simultaneous from sequential use and sharing 
of syringes), these results confirm that injecting polydrug 
use may be common among some groups of people who 
inject drugs. Polydrug use increases the risk of drug-
related harms: the co-injection of cocaine and heroin 
amplifies the negative cardiovascular effects of cocaine, 
while cocaine can mask the sedative effects of opioids, 
increasing the risk of delayed overdose (EMCDDA, 2017). 
Co-use of cocaine is associated with poorer compliance 
with opioid substitution treatment (Rowan-Szal et al., 
2000). The combination of opioids and benzodiazepines 
increases the risk of overdose. Harm reduction and drug 
treatment services need to provide information on the 
health risks associated with these specific combinations of 
substances.
19
Results from the ESCAPE project 2017 I May 2019
l Conclusion
The ESCAPE approach provides local information that can 
be used for local interventions. It complements existing 
monitoring tools (such as surveillance data from drug 
treatment centres) but does not replace them. Well-
designed observational studies, collecting behavioural 
data and qualitative information from interviews with drug 
users in low-threshold services or using respondent driven 
sampling, are still the best tools to obtain information on 
many aspects of injecting, including reuse and sharing. 
Nevertheless, the timely, laboratory-confirmed local data 
on injected substances and patterns of injection provided 
by the ESCAPE approach can help to guide local 
responses. Importantly, by collecting injecting material 
from street bins, it potentially provides information on 
groups of people who inject drugs that are not reached by 
health services.
A second syringe collection campaign, expanded to 
include more cities, was carried out in 2018. By analysing 
trends over time, the network will aim to detect changing 
patterns of injecting. Future collection campaigns will 
further harmonise the sampling strategy, the type of 
syringes collected and the list of substances tested across 
cities. Future campaigns should also aim at collecting 
syringes from other settings and including more cities in 
order to provide a more representative picture of the 
European situation and to advance knowledge on local 
injecting practices.
Pros and cons of the method
The method used in this study:
+ provides timely local information on injected 
substances and patterns of injection to health and 
social services, allowing for prompt response to 
potentially dangerous substances;
+ provides analytically confirmed information that 
can complement existing monitoring tools based 
on self-reports from users;
+ provides information on injecting practices of 
groups of people who inject drugs that are not 
reached by drug treatment services;
+ can potentially detect changes in injected 
substances if repeated over time;
– can be costly and resource-intensive in terms of 
syringe collection, transport, sample preparation 
and laboratory analysis;
– requires strict safety measures;
– requires strong laboratory and analytical 
chemistry expertise;
– does not replace surveys among drug users.
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l ESCAPE network
City Names Institutions Logo
Amsterdam Tibor Brunt Trimbos instituut
Toon Broeks MAINline
Budapest Klára Keveházi
Hungarian 
Interchurch Aid
József Csorba
Tamás Figeczki
Glasgow Dr Andrew McAuley Health Protection 
Scotland / Glasgow 
Caledonian University
Denise McKeown University of Glasgow
Dr Hazel Torrance
John Campbell NHS Greater Glasgow 
and Clyde
Dr Carole Hunter
Helsinki Teemu Gunnar National Institute for 
Health and Welfare
Anne Arponen
Lausanne Elodie Lefrançois Université de 
Lausanne
Pierre Esseiva Université de 
Lausanne
Marc Augsburger CHUV
Paris Sara Karolak Paris Sud
University
Aziz Kinani
Maya Bimbot
Yves Levi
Catherine Duplessy association SAFE
Julien Van der Elst
Bienvenue Mbadu 
Kambu
Thierry Grandidier
Scientific 
coordination
Thomas Néfau Observatoire Français 
des drogues et des 
toxicomanies
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l Appendices
APPENDIX 1:
List of drugs, adulterants and metabolites tested for, by city, ESCAPE 2017
Group Substance Amsterdam (1) Budapest (1) Glasgow (2) Helsinki (3) Lausanne (1) Paris (4)
Amphetamines
Amphetamine x x x x x x
Methamphetamine x x x x x x
Cocaine Cocaine x x x x x x
Heroin Heroin x x x x x x
Morphine Morphine x x x x x x
Buprenorphine Buprenorphine x x x x x x
Naloxone Naloxone x x x x x
Methadone Methadone x x x x x x
Fentanyl and 
derivatives
3-methylfentanyl x x x x
4-Chloro-isobutyrfentanyl x x x (x) x
4-Fluoro-isobutyryl fentanyl x x x (x) x
4-Methoxy-butyryl fentanyl x x x (x) x
Acetylfentanyl x x x x x x
Acrylfentanyl x x x x x
Alfentanil x x x x x
Butyrylfentanyl x x x (x) x
Carfentanil x x x x x x
Cyclopentylfentanyl x x x (x) x
Cyclopropylfentanyl x x x (x) x
Despropionylfentanyl x x x (x) x
Fentanyl x x x x x x
Furanyl fentanyl x x x x x x
Ocfentanyl x x x x x x
ortho-Fluorofentanyl x x x (x) x
Valerylfentanyl x x x (x) x
Other opioids
AH-7921 x x x (x) x
Codeine x x x x x x
Dihydrocodeine x x x x x
Hydrocodone x x x x
Oxycodone x x x x
Tramadol x x x x x x
U-47,700 x x x x x x
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Group Substance Amsterdam (1) Budapest (1) Glasgow (2) Helsinki (3) Lausanne (1) Paris (4)
Cathinones
3-MMC x x x x x x
3,4-DMMC x x x x
4-Chloro-alpha-PVP x x x x
4-Chloroethcathinone x x x x
4-Chloromethcathinone x x x (x) x
4-Fluoro-alpha-PVP x x x x
4-MEC x x x x x x
alpha-PHP x x x x
alpha-PHPp x x x x
alpha-PVP x x x x x x
bk-MDDMA x x x x
Buphedrone (MABP) x x x x
Butylone (bk-MDMB) x x x x x
Ethylone (bk-MDEA) x x x x x
MDPBP x x x x
MDPV x x x x x x
Mephedrone (4-MMC) x x x x x x
Methedrone (bk-PMMA) x x x x
Methylone x x x x x x
Mexedrone x x x (x) x
Naphyrone x x x (x) x
N-ethylhexedrone x x (x) x
Pentedrone x x x x x x
Synthetic 
cannabinoids
4CN-Cumyl-BINACA x x
5F-APINACA x x x x
5F-MDMB-PINACA x x (x) x
5F-PB-22 x x x x
AB-CHMINACA x x x x
AB-FUBINACA x x x x
AMB-FUBINACA x x (x) x
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Group Substance Amsterdam (1) Budapest (1) Glasgow (2) Helsinki (3) Lausanne (1) Paris (4)
Benzodiazepines
3OH-Phenazepam x x x x x
Alprazolam x x x x x x
Bromazepam x x x x
Chlordiazepoxide x x x x x
Clobazam x x x x
Clonazepam x x x x x x
Clonazolam x x x (x) x
Delorazepam x x x (x) x
Deschloroetizolam x x x x x
Desmethyldiazepam x x x x x
Diazepam x x x x x x
Diclazepam x x x x x
Etizolam x x x x x x
Flubromazepam x x x x x
Flubromazolam x x x (x) x
Flunitrazepam x x x x x
Lorazepam x x x x x
Lormetazepam x x x (x) x
Meclonazepam x x x (x) x
Metizolam x x x (x) x
Midazolam x x x x x x
Nifoxipam x x x x x
Nitrazepam x x x x x
Oxazepam x x x x x x
Phenazeam x x x x x
Pyrazolam x x x x x
Temazepam x x x x x x
Piperidines
2-DPMP x x
3,4-CTMP x x
4-Fluoro-methylphenidate x x x x
Ethylphenidate x x x x x x
Methylphenidate x x x x x x
MDMA
MDA x x x x x
MDEA x x x x x
MDMA x x x x x x
Ketamine Ketamine x x x x x x
Other 
medications
Bupropion x x x x
Carbamazepine x x x x
Gabapentin x x x x
Methiopropamine x x x x x x
Methotrexate x x (x) x x
Pregabalin x x x x
Quetiapine x x x x
Tiapride x x (x) x
Tizanidine x x x x
Zolpidem x x x x x x
Zopiclone x x x x x x
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Group Substance Amsterdam (1) Budapest (1) Glasgow (2) Helsinki (3) Lausanne (1) Paris (4)
Other 
amphetamines
3-Fluoromethamphetamine x x x x
4-Fluoro-amphetamine x x x x x
N-propylamphetamine x x (x) x
PMA x x x x
PMMA x x x x
Other drugs
5-EAPB x x x x
Mephtetramine x x x x
Metabolites
6-monoacetylmorphine 
(heroin)
x x x x x x
7-Aminoclonazepam 
(clonazepam)
x x x x
7-Aminoflunitrazepam 
(flunitrazepam)
x x x x
7-Aminonitrazepam 
(nitrazepam)
x x
10-monohydroxycarbamaze-
pine (carbamazepine)
x x x x
α-hydroxy-alprazolam 
(alprazolam)
x x x x
α-hydroxy-midazolam 
(midazolam)
x x x x
Acetylcodeine (heroine) x x x x
Benzoylecgonine (cocaine) x x x x x x
EDDP (methadone) x x x x
HMMA (MDMA) x x x x
norbuprenorphine 
(buprenorphine)
x x x x
O-desmethyltramadol 
(tramadol)
x x x x
Adulterants
Caffeine x x x
Dextromethorphan x x x x x x
Griseofulvine x x x
Hydroxyzine x x x x
Levamisole x x x x x x
Lidocaine x x x
Paracetamol x x x
Phenacetin x x x
(1) Screening method — gas chromatography/mass spectrometry detection.
(2) Target method — high performance liquid chromatography/mass spectrometry detection.
(3) Target method — high performance liquid chromatography/tandem mass spectrometry + ultra-high performance liquid chromatography/quadrupole 
time-of-flight (QToF) detection (only if there were no positive findings with the first analytical method). Substances with ‘x’ in brackets were only screened with 
the second analytical method (QToF).
(4) Target method — high performance liquid chromatography/tandem mass spectrometry detection.
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